TempraMed Announces Strategic Agreement with Maccabi Healthcare Services, a Leading HMO with over 2.8 Million Patients

Executive Summary

• TempraMed Technologies Ltd. announced that its flagship products, the VIVI Cap and VIVI EPI, are now available through Maccabi Healthcare Services, Israel’s second‑largest HMO serving over 2.8 million members.
• The agreement represents a major commercial milestone and expands TempraMed’s distribution footprint into a key international market, complementing existing sales channels that include Amazon, Target, Walgreens, Walmart, CVS, McKesson, Cardinal Health and Humana.
• TempraMed highlighted its growing product pipeline (additional medication formats, digital tracking models) and reiterated its path toward revenue and cash‑flow positivity driven by institutional partnerships and consumer demand.

Key Details

• Partnership Scope: Products VIVI Cap (insulin protection) and VIVI EPI (EpiPen™ protection) will be offered to Maccabi’s 2.8 million members across Israel.
• Commercial Impact: Marks the company’s entry into a major HMO channel, expanding its global reach beyond North America and Europe.
• Sales History: Over 120,000 devices sold worldwide to date; existing distribution through major retailers and healthcare distributors in the U.S. and Canada.
• Product Technology: Patented deep‑vacuum insulator combined with phase‑change material; battery‑free, refrigeration‑free temperature control for “in‑use” injectables.
• Strategic Rationale (CEO Quote): “This milestone is more than just a commercial agreement—it’s a validation of our long‑term vision and growth strategy…accelerating access to life‑enhancing technology for millions.”
• Partner Statement: Dorit Eppler, Director, Maccabi Pharm., noted the solution aligns with Maccabi’s goal to provide practical tools that give diabetic patients confidence in medication management.
• Future Pipeline: Plans to introduce formats for GLP‑1s and other biologics, blood transportation devices, and digital models featuring real‑time tracking and personalized health data.
• Financial Outlook: Management emphasized a clear path to meaningful revenue and cash‑flow positivity through institutional partnerships, growing consumer demand, and an IP‑protected product line.

Notable Quotes

“By partnering with an innovative leader like Maccabi, we’re accelerating access to life‑enhancing technology for millions who need it.” – Ron Nagar, CEO, TempraMed Technologies Ltd.

“The implementation of TempraMed’s solution is in line with Maccabi Pharm’s goal of providing practical and effective tools that give diabetic patients confidence…” – Dorit Eppler, Director, Maccabi Pharm.